Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,868
Views
36
CrossRef citations to date
0
Altmetric
Back Matter

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

Julie Charlesa Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;b Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Laurence Chaperota Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;c R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, FranceView further author information
,
Dalil Hannanid Immune checkpoint inhibitors, PDC*line Pharma, GrenobleView further author information
,
Juliana Bruder Costaa Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;b Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, France;c R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, FranceView further author information
,
Isabelle Templierb Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Sabiha Trabelsib Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Hugo Gile Pathology Department, Institut de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Anaick Moisana Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;f Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, FranceView further author information
,
Virginie Persoonsf Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, FranceView further author information
,
Harald Hegelhoferf Cell Therapy and Engineering Unit, Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint Ismier, FranceView further author information
,
Edith Schirg Délégation à la Recherche Clinique et à l’Innovation, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Jean-Louis Quesadah Centre d’investigation Clinique, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Christophe Mendozah Centre d’investigation Clinique, CHU Grenoble Alpes, Grenoble, FranceView further author information
,
Caroline Asporda Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;c R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, FranceView further author information
,
Olivier Manchesa Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;c R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, FranceView further author information
,
Pierre G. Couliei de Duve Institute, Université Catholique de Louvain, Brussels, BelgiumView further author information
,
Amir Khammarij Onco-dermatology Department, CHU Nantes, CIC 1413, CRCINA, Nantes University, Nantes, FranceView further author information
,
Brigitte Drenoj Onco-dermatology Department, CHU Nantes, CIC 1413, CRCINA, Nantes University, Nantes, FranceView further author information
,
Marie-Thérèse Lecciaa Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;b Dermatology Department, Pôle Pluridisciplinaire de Médecine, CHU Grenoble Alpes, Grenoble, FranceView further author information
&
Joel Plumasa Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France;c R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France;d Immune checkpoint inhibitors, PDC*line Pharma, GrenobleCorrespondence[email protected]
View further author information
 show all
Article: 1738812 | Received 22 Jul 2019, Accepted 28 Jan 2020, Published online: 12 Apr 2020

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Michal Hensler, Jana Rakova, Lenka Kasikova, Tereza Lanickova, Josef Pasulka, Peter Holicek, Marek Hraska, Tereza Hrnciarova, Pavla Kadlecova, Andreu Schoenenberger, Klara Sochorova, Daniela Rozkova, Ludek Sojka, Jana Drozenova, Jan Laco, Rudolf Horvath, Michal Podrazil, Guo Hongyan, Tomas Brtnicky, Michal J. Halaska, Lukas Rob, Ales Ryska, An Coosemans, Ignace Vergote, Abhishek D. Garg, David Cibula, Jirina Bartunkova, Radek Spisek & Jitka Fucikova. (2022) Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. OncoImmunology 11:1.
Read now
Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, an Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao & Abhishek D Garg. (2022) Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 11:1.
Read now
Chunmei Fu, Tianle Ma, Li Zhou, Qing-Sheng Mi & Aimin Jiang. (2022) Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities. Immunological Investigations 51:8, pages 2133-2158.
Read now

Articles from other publishers (33)

Anthony Maino, Axelle Amen, Joël Plumas, Lucie Bouquet, Marina Deschamps, Philippe Saas, Laurence Chaperot & Olivier Manches. (2024) Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell–Based Approach for the Expansion and Characterization of SARS-CoV-2–Specific T Cells. The Journal of Immunology 212:5, pages 825-833.
Crossref
Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis & Jiekun Yang. (2024) Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. Clinical & Experimental Metastasis.
Crossref
Matilde Monti, Giorgia Ferrari, Valentina Grosso, Francesco Missale, Mattia Bugatti, Valeria Cancila, Stefania Zini, Agnese Segala, Luca La Via, Francesca Consoli, Matteo Orlandi, Alessandra Valerio, Claudio Tripodo, Marzia Rossato & William Vermi. (2024) Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift. Frontiers in Immunology 14.
Crossref
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen & Daichao Wu. (2024) Advances, opportunities and challenges in developing therapeutic cancer vaccines. Critical Reviews in Oncology/Hematology 193, pages 104198.
Crossref
Ye Zheng, Xiaoyu Ma, Shouchang Feng, Hongtao Zhu, Xin Chen, Xingjiang Yu, Kai Shu & Suojun Zhang. (2023) Dendritic cell vaccine of gliomas: challenges from bench to bed. Frontiers in Immunology 14.
Crossref
Shumin Luo, Jing Chen, Fang Xu, Huan Chen, Yiru Li & Weihua Li. (2023) Dendritic Cell-Derived Exosomes in Cancer Immunotherapy. Pharmaceutics 15:8, pages 2070.
Crossref
Nausicaa Malissen & Jean-Jacques Grob. (2023) Treatment of Recurrent Melanoma Following Adjuvant Therapy. American Journal of Clinical Dermatology 24:3, pages 333-341.
Crossref
Eleonora Sosa Cuevas, Philippe Saas & Caroline Aspord. (2023) Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation. Cancers 15:8, pages 2206.
Crossref
Julia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts & Bart Neyns. (2023) Current “state of the art” on dendritic cell-based cancer vaccines in melanoma. Current Opinion in Oncology 35:2, pages 87-93.
Crossref
Yunchao Zhang, Chenxin Liu, Chunjie Wu & Linjiang Song. (2023) Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives. Biomedicine & Pharmacotherapy 159, pages 114257.
Crossref
Sangeeta Goswami, Swetha Anandhan, Deblina Raychaudhuri & Padmanee Sharma. (2022) Myeloid cell-targeted therapies for solid tumours. Nature Reviews Immunology 23:2, pages 106-120.
Crossref
Dalil Hannani, Estelle Leplus, Karine Laulagnier, Laurence Chaperot & Joël Plumas. (2023) Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. Genes & Cancer 14, pages 3-11.
Crossref
Dalil Hannani, Estelle Leplus, David Laurin, Benjamin Caulier, Caroline Aspord, Natacha Madelon, Ekaterina Bourova-Flin, Christian Brambilla, Elisabeth Brambilla, Anne-Claire Toffart, Karine Laulagnier, Laurence Chaperot & Joël Plumas. (2023) A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients. International Journal of Molecular Sciences 24:3, pages 1897.
Crossref
Melissa N. Thone, Jee Young Chung, Dominique Ingato, Margaret L. Lugin & Young Jik Kwon. (2022) Cell‐Free, Dendritic Cell‐Mimicking Extracellular Blebs for Molecularly Controlled Vaccination. Advanced Therapeutics 6:1.
Crossref
Abigail G. Harvey, Athens M. Graves, Chandana K. Uppalapati, Saoirse M. Matthews, Stephanie Rosenberg, Emma G. Parent, Madison H. Fagerlie, Jack Guinan, Brina S. Lopez & Lisa M. Kronstad. (2022) Dendritic cell-natural killer cell cross-talk modulates T cell activation in response to influenza A viral infection. Frontiers in Immunology 13.
Crossref
Sabina Sánchez Hernández, Martin Roelsgaard Jakobsen & Rasmus O. Bak. (2022) Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. International Journal of Molecular Sciences 23:19, pages 11397.
Crossref
Jingyi Xia, Yangbao Miao, Xi Wang, Xiaobing Huang & Jingying Dai. (2022) Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomedicine & Pharmacotherapy 152, pages 113250.
Crossref
Liwen Su, Xin Chen, Jingyi Zhang & Fangrong Yan. (2022) Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials. JCO Precision Oncology:6.
Crossref
Jinpu Yang, Xia Liu, Yiwen Cheng, Jingchen Zhang, Feng Ji & Zongxin Ling. (2022) Roles of Plasmacytoid Dendritic Cells in Gastric Cancer. Frontiers in Oncology 12.
Crossref
Joël Plumas. (2022) Harnessing dendritic cells for innovative therapeutic cancer vaccines. Current Opinion in Oncology 34:2, pages 161-168.
Crossref
Cui Fan, Jichang Wu, Yilin Shen, Haixia Hu, Quan Wang, Yufeng Mao, Bin Ye & Mingliang Xiang. (2021) Hypoxia promotes the tolerogenic phenotype of plasmacytoid dendritic cells in head and neck squamous cell carcinoma. Cancer Medicine 11:4, pages 922-930.
Crossref
Xianzhu Fang, Zhiliang Guo, Jinqing Liang, Jiao Wen, Yuanyuan Liu, Xiumei Guan & Hong Li. (2022) Neoantigens and their potential applications in tumor immunotherapy (Review). Oncology Letters 23:3.
Crossref
Chunmei Fu, Li Zhou, Qing-Sheng Mi & Aimin Jiang. (2022) Plasmacytoid Dendritic Cells and Cancer Immunotherapy. Cells 11:2, pages 222.
Crossref
Dipyaman GangulyDipyaman Ganguly. 2022. Plasmacytoid Dendritic Cells. Plasmacytoid Dendritic Cells 147 160 .
Eleonora Sosa Cuevas, Nathalie Bendriss‐Vermare, Stephane Mouret, Florence De Fraipont, Julie Charles, Jenny Valladeau‐Guilemond, Laurence Chaperot & Caroline Aspord. (2022) Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80 + PDL1 − )‐pDC subset negatively correlated with clinical outcomes in melanoma patients . Clinical & Translational Immunology 11:5.
Crossref
Yi Yao, Chunmei Fu, Li Zhou, Qing-Sheng Mi & Aimin Jiang. (2021) DC-Derived Exosomes for Cancer Immunotherapy. Cancers 13:15, pages 3667.
Crossref
Olga Zimmermannova, Inês Caiado, Alexandra G. Ferreira & Carlos-Filipe Pereira. (2021) Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Frontiers in Immunology 12.
Crossref
Junhua Mai, Zhaoqi Li, Xiaojun Xia, Jingxin Zhang, Jun Li, Haoran Liu, Jianliang Shen, Maricela Ramirez, Feng Li, Zheng Li, Kenji Yokoi, Xuewu Liu, Elizabeth A. Mittendorf, Mauro Ferrari & Haifa Shen. (2021) Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. Advanced Science 8:12.
Crossref
Kevin Lenogue, Alexandre Walencik, Karine Laulagnier, Jean-Paul Molens, Houssem Benlalam, Brigitte Dreno, Pierre Coulie, Martin Pule, Laurence Chaperot & Joël Plumas. (2021) Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells. Vaccines 9:2, pages 141.
Crossref
Amanda L. Wooster, Lydia H. Girgis, Hayley Brazeale, Trevor S. Anderson, Laurence M. Wood & Devin B. Lowe. (2021) Dendritic cell vaccine therapy for colorectal cancer. Pharmacological Research 164, pages 105374.
Crossref
Pauline Girard, Eleonora Sosa Cuevas, Benedicte Ponsard, Stephane Mouret, Hugo Gil, Edwige Col, Florence De Fraipont, Nathalie Sturm, Julie Charles, Olivier Manches, Laurence Chaperot & Caroline Aspord. (2021) Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes. Clinical & Translational Immunology 10:11.
Crossref
Chunmei Fu, Li Zhou, Qing-Sheng Mi & Aimin Jiang. (2020) DC-Based Vaccines for Cancer Immunotherapy. Vaccines 8:4, pages 706.
Crossref
Eleonora Sosa Cuevas, Laurissa Ouaguia, Stephane Mouret, Julie Charles, Florence De Fraipont, Olivier Manches, Jenny Valladeau‐Guilemond, Nathalie Bendriss‐Vermare, Laurence Chaperot & Caroline Aspord. (2020) BDCA1 + cDC2s, BDCA2 + pDCs and BDCA3 + cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients . Clinical & Translational Immunology 9:11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.